Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Propanc Biopharma ( (PPCB) ) has provided an announcement.
On November 4, 2025, Propanc Biopharma completed a Securities Purchase Agreement with Hexstone Capital LLC, resulting in the sale of 100 shares of Series C Preferred Stock and a warrant for additional shares, raising over $1 million. This transaction, alongside the amendment of the company’s Certificate of Incorporation to authorize a new series of preferred stock, positions Propanc Biopharma to potentially enhance its financial flexibility and strategic growth initiatives.
More about Propanc Biopharma
Propanc Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of cancer treatments. The company is engaged in creating therapies that target and eradicate cancer stem cells, aiming to improve patient outcomes and survival rates.
Average Trading Volume: 1,857,252
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.19M
See more data about PPCB stock on TipRanks’ Stock Analysis page.